Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 5, 2010, Pages 1381-1386

  Barriger, R Bryan ^a   Fakiris, Achilles J ^a   Hanna, Nasser ^b   Yu, Menggang ^a   Mantravadi, Prasad ^c   McGarry, Ronald C ^d  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Radiation Oncology Associates   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Chemoradiation; Non small cell lung cancer; Pneumonitis; Toxicity

Indexed keywords

ADVERSE EVENTS; CHEMORADIATION; CHEMORADIOTHERAPY; CISPLATINUM; DOCETAXEL; DOSE-VOLUME ANALYSIS; ETOPOSIDE; MEAN LUNG DOSE; NON SMALL CELL LUNG CANCER; OVERALL RATE; PNEUMONITIS; PREDICTIVE FACTORS; PROSPECTIVE RANDOMIZED TRIAL; RADIATION PNEUMONITIS; RADIATION THERAPY; RISK FACTORS;

BIOLOGICAL ORGANS; DRUG PRODUCTS; PATIENT MONITORING; TOXICITY;

RADIOTHERAPY;

CISPLATIN; DOCETAXEL; ETOPOSIDE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CIGARETTE SMOKING; DISEASE COURSE; DISEASE SEVERITY; DOSIMETRY; FOLLOW UP; GROUPS BY AGE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE DISTRIBUTION; RADIATION PNEUMONIA; RETROSPECTIVE STUDY; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; HUMANS; LUNG; LUNG NEOPLASMS; MIDDLE AGED; RADIATION PNEUMONITIS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TAXOIDS; TUMOR BURDEN;

EID: 78549270394     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.09.030     Document Type: Article

References (22)

1. T. Rancati, G.L. Ceresoli, and G. Gagliardi Factors predicting radiation pneumonitis in lung cancer patients: A retrospective study Radiother Oncol 67 2003 275 283
2. J.D. Bradley, A. Hope, and I. El Naqa A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data Int J Radiat Oncol Biol Phys 69 2007 985 992
3. Y. Seppenwoolde, K. De Jaeger, and L.J. Boersma Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer Int J Radiat Oncol Biol Phys 60 2004 748 758
4. A.J. Hope, P.E. Lindsay, and I. El Naqa Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters Int J Radiat Oncol Biol Phys 65 2006 112 124
5. M.L. Hernando, L.B. Marks, and G.C. Bentel Radiation-induced pulmonary toxicity: A dose-volume histogram analysis in 201 patients with lung cancer Int J Radiat Oncol Biol Phys 51 2001 650 659
6. H. Jin, S.L. Tucker, and H.H. Liu Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy Radiother Oncol 2008
7. T.J. Robnett, M. Machtay, and E.F. Vines Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer Int J Radiat Oncol Biol Phys 48 2000 89 94
8. E.D. Yorke, A. Jackson, and K.E. Rosenzweig Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy Int J Radiat Oncol Biol Phys 54 2002 329 339
9. M. Fay, A. Tan, and R. Fisher Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy Int J Radiat Oncol Biol Phys 61 2005 1355 1363
10. T.H. Kim, K.H. Cho, and H.R. Pyo Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer Radiology 235 2005 208 215
11. F.M. Kong, J.A. Hayman, and K.A. Griffith Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): Predictors for radiation pneumonitis and fibrosis Int J Radiat Oncol Biol Phys 65 2006 1075 1086
12. S.L. Kwa, J.V. Lebesque, and J.C. Theuws Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients Int J Radiat Oncol Biol Phys 42 1998 1 9
13. S. Wang, Z. Liao, and X. Wei Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT) Int J Radiat Oncol Biol Phys 66 2006 1399 1407
14. M.V. Graham, J.A. Purdy, and B. Emami Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) Int J Radiat Oncol Biol Phys 45 1999 323 329
15. K. Tsujino, S. Hirota, and M. Endo Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer Int J Radiat Oncol Biol Phys 55 2003 110 115
16. M. Meadors, J. Floyd, and M.C. Perry Pulmonary toxicity of chemotherapy Semin Oncol 33 2006 98 105
17. C. Kouroussis, D. Mavroudis, and S. Kakolyris High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: Results of a dose-finding study Lung Cancer 44 2004 363 368
18. Y. Segawa, N. Takigawa, and M. Kataoka Risk factors for development of radiation pneumonitis following radiation therapy with or without chemotherapy for lung cancer Int J Radiat Oncol Biol Phys 39 1997 91 98
19. N. Hanna, M. Neubauer, and C. Yiannoutsos Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology J Clin Oncol 26 2008 5755 5760
20. D.R. Gandara, K. Chansky, and K.S. Albain Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504 J Clin Oncol 21 2003 2004 2010
21. K.S. Albain, J.J. Crowley, and A.T. Turrisi 3rd Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group phase II study, SWOG 9019 J Clin Oncol 20 2002 3454 3460
22. Z. Kocak, E.S. Evans, and S.M. Zhou Challenges in defining radiation pneumonitis in patients with lung cancer Int J Radiat Oncol Biol Phys 62 2005 635 638